Hepatitis Forums
Hepatitis B Main Forums => Hepatitis B => Topic started by: Hep Editors on August 19, 2020, 10:09:20 am
-
Researchers have challenged findings from a Chinese study that concluded Baraclude (entecavir) is associated with a lower risk of liver cancer than Viread (tenofovir disoproxil fumarate) for treatment of hepatitis B virus (HBV), Infectious Disease Advisor reports.
Publishing their opinions in a letter in the journal Gastroenterology, the researchers stated that the Chinese team’s claims about Baraclude’s superior safety run contrary to the findings of previous studies, which found no differences in the long-term risk of liver cancer between people treated for HBV for the first time with Baraclude versus Viread.
Read more...
https://www.hepmag.com/article/viread-safer-baraclude-hep-b-fast